Artemisinin-based combination therapies (ACTs) have demonstrated in vitro inhibition of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Artemisinins have also shown anti-inflammatory effects, including inhibition of interleukin-6 (IL-6) that plays a key role in the development of severe coronavirus disease 2019 (COVID-19). There is now sufficient evidence for the effectiveness of ACTs, and in particular artesunate/pyronaridine, to support clinical studies for COVID-19 infections.

中文翻译：

---

重新利用抗疟药来应对 COVID-19 大流行

基于青蒿素的联合疗法 (ACTs) 已证明对严重急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2) 的体外抑制作用。青蒿素还显示出抗炎作用，包括抑制在 2019 年严重冠状病毒病 (COVID-19) 发展中起关键作用的白介素 6 (IL-6)。现在有足够的证据证明 ACTs，特别是青蒿琥酯/吡那啶的有效性，以支持 COVID-19 感染的临床研究。